Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31.9M
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
15.3M
-
Shares change
-
+421K
-
Total reported value, excl. options
-
$38.3M
-
Value change
-
+$857K
-
Put/Call ratio
-
0.13
-
Number of buys
-
14
-
Number of sells
-
-28
-
Price
-
$2.50
Significant Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) as of Q1 2025
63 filings reported holding VTGN - Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.3M shares
of 31.9M outstanding shares and own 48.06% of the company stock.
Largest 10 shareholders include TCG Crossover Management, LLC (2.68M shares), Nantahala Capital Management, LLC (1.98M shares), VANGUARD GROUP INC (1.96M shares), STEMPOINT CAPITAL LP (1.75M shares), COMMODORE CAPITAL LP (1.58M shares), SPHERA FUNDS MANAGEMENT LTD. (791K shares), JPMORGAN CHASE & CO (751K shares), Ikarian Capital, LLC (602K shares), DIADEMA PARTNERS LP (566K shares), and ADAR1 Capital Management, LLC (421K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.